Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for IDEAYA Biosciences (IDYA) over the last 7 years, with Q1 2025 value amounting to $6.2 million.

  • IDEAYA Biosciences' Gains from Investment Securities fell 5733.79% to $6.2 million in Q1 2025 from the same period last year, while for Dec 2025 it was $6.2 million, marking a year-over-year decrease of 8066.88%. This contributed to the annual value of $6.2 million for FY2025, which is 8066.88% down from last year.
  • IDEAYA Biosciences' Gains from Investment Securities amounted to $6.2 million in Q1 2025, which was down 5733.79% from $1.6 million recorded in Q4 2024.
  • In the past 5 years, IDEAYA Biosciences' Gains from Investment Securities registered a high of $14.5 million during Q1 2024, and its lowest value of -$2.4 million during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is $3.3 million, with a median of $1.3 million in 2023.
  • Data for IDEAYA Biosciences' Gains from Investment Securities shows a peak YoY increase of 1510000.0% (in 2021) and a maximum YoY decrease of 104641.15% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Gains from Investment Securities stood at -$2.4 million in 2021, then soared by 125.04% to $600000.0 in 2022, then surged by 2050.0% to $12.9 million in 2023, then tumbled by 87.6% to $1.6 million in 2024, then skyrocketed by 286.62% to $6.2 million in 2025.
  • Its Gains from Investment Securities stands at $6.2 million for Q1 2025, versus $1.6 million for Q4 2024 and $3.4 million for Q3 2024.